Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO Dror Bashan will deliver a presentation on Monday, September 8, 2025, at 3:30 PM EDT in the Holmes II Room at the Lotte New York Palace Hotel. The management team will also engage in one-on-one meetings with registered investors throughout the conference.

CARMIEL, Israel, Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference which is being held on September 8–10, 2025 at the Lotte New York Palace Hotel, New York City, NY.

Mr. Bashan will present on Monday, September 8, at 3:30 p.m. Eastern Daylight Time (EDT) in the Holmes II Room, Fourth Floor. Management will participate in one-on-one meetings throughout the conference with registered investor attendees.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio^®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.

Investor Contact

Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543639.html

SOURCE Protalix Biotherapeutics Inc.

FAQ

When is Protalix BioTherapeutics (PLX) presenting at the H.C. Wainwright Conference?

Protalix BioTherapeutics will present on Monday, September 8, 2025, at 3:30 PM EDT in the Holmes II Room, Fourth Floor of the Lotte New York Palace Hotel.

Who will be presenting for Protalix BioTherapeutics (PLX) at the H.C. Wainwright Conference?

Dror Bashan, the Company's President and Chief Executive Officer, will be presenting at the conference.

Where is the H.C. Wainwright Conference being held for Protalix BioTherapeutics (PLX)?

The conference is being held at the Lotte New York Palace Hotel in New York City, NY from September 8-10, 2025.

What type of meetings will Protalix BioTherapeutics (PLX) management conduct at the conference?

Management will conduct one-on-one meetings with registered investor attendees throughout the conference.